1986
DOI: 10.1111/j.1476-5381.1986.tb14579.x
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177)

Abstract: In order to elucidate the role of endogenous thromboxane A2 in myocardial ischaemia, cats were subjected to 5 h of permanent occlusion of the left anterior descending coronary artery (LAD) and treated with the thromboxane receptor antagonist BM 13.177 (5 mg kg−1 h−1, i.v.). In comparison with vehicle‐treated LAD‐occluded cats, BM 13.177 significantly attenuated the loss of creatine phosphokinase‐specific activity from the ischaemic myocardium and antagonized the ischaemia‐induced rise in the ST‐segment of the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
10
0

Year Published

1987
1987
2001
2001

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 44 publications
(10 citation statements)
references
References 23 publications
0
10
0
Order By: Relevance
“…29 Conversely, there are controversial reports regarding the cardioprotective effect of TP antagonists. Although beneficial effects of TP antagonists have been reported, 16 an absence of their protective effects on cardiac I/R injury has also been reported. 17 This discrepancy may result from the fact that some TP antagonists cross-act on other prostanoid receptors, such as EP 3 , 30 through which PGE 2 was reported to exert protective effects on cardiac I/R injury.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…29 Conversely, there are controversial reports regarding the cardioprotective effect of TP antagonists. Although beneficial effects of TP antagonists have been reported, 16 an absence of their protective effects on cardiac I/R injury has also been reported. 17 This discrepancy may result from the fact that some TP antagonists cross-act on other prostanoid receptors, such as EP 3 , 30 through which PGE 2 was reported to exert protective effects on cardiac I/R injury.…”
Section: Discussionmentioning
confidence: 99%
“…14 -16 The beneficial effects of TX synthase inhibitors on cardiac I/R injury were attributed to enhanced generation of PGI 2 derived from increased availability of its precursor, resulting in inhibition of neutrophil adhesion to endothelial cells. 14,15,17 The cardioprotective effects of TP antagonists, however, are variable, according to the reports, 16,17 and therefore, the role of TXA 2 in I/R injury has not been established.…”
mentioning
confidence: 99%
“…vascular trauma associated with surgery; vascular instrumentation by catheters) resulting in endothelial cell damage, enhanced thromboxane B2 plasma levels, as well as thrombocytopenia which may therefore artificially influence platelet function in vivo (Schror & Thiemermann, 1986).…”
Section: Haemodynamic Measurementsmentioning
confidence: 99%
“…Coronary vasospasm, platelet aggregation, and loss of myocardial cell integrity induced by increased localized production of TxA2 could propagate ischemic damage once myocardial ischemia is initiated. In this regard, thromboxane synthetase inhibitors and thromboxane receptor antagonists have been reported to reduce the ischemic damage to the myocardium after acute coronary artery ligation (12)(13)(14).…”
mentioning
confidence: 99%